IDH inhibitors (IDHi) selectively target mutant IDH enzymes, suppressing 2-HG production to restore metabolic homeostasis and normalize epigenetic patterns, thereby inducing AML cell differentiation while suppressing proliferation [116,117]. The gene discussed is IDH2; the disease is acute myeloid leukemia.